• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Senseonics beats The Street in Q1 following Eversense E3 launch

May 11, 2022 By Sean Whooley

Senseonics Eversense E3 Ascensia Diabetes Care
The Eversense E3 system. [Image from Ascensia/Senseonics]
Senseonics (NYSE:SENS) posted first-quarter results that topped the consensus revenue forecast on Wall Street.

The Germantown, Maryland-based company posted profits of $86.7 million, or 19¢ per share, on sales of $2.5 million for the three months ended March 31, 2022, for a massive bottom-line gain from losses of $249.5 million this time last year despite a sales decline of 12.8%.

Adjusted to exclude one-time items, losses per share were 3¢, falling level with projections on Wall Street, where analysts were looking for sales of $2.2 million.

The main highlight for the quarter came in the form of FDA approval for Senseonics’ next-generation Eversense E3 180-day continuous glucose monitor. Less than two months later, the company announced the first patient implant of Eversense E3 in the U.S.

“We are excited to have received FDA approval and be underway with a comprehensive launch campaign for Eversense E3, the world’s longest-lasting CGM system,” Senseonics President and CEO Tim Goodnow said in a news release. “From awareness and access to training and operations, Senseonics and Ascensia are coordinating to engage patients and HCP’s to experience the differentiated benefits of our longer duration next generation sensor – inserting the first patient with E3 just six weeks following FDA approval. We are now focused on bringing the E3 implantable CGM with six months of wear to more people with diabetes in the U.S.”

Senseonics reiterated its 2022 guidance, projecting revenues between $14 million and $18 million.

SENS shares closed yesterday — the day it released its earnings results — up 8.8%, but shares were down 8.9% in pre-market trading today.

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Patient Monitoring, Technology, Wall Street Beat Tagged With: Ascensia Diabetes Care, Senseonics

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS